Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there were an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of hematologic and solid cancers. Su
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 27, 2015 Research and ... Jain PharmaBiotech,s new report "Cell Therapy - ... This report describes and evaluates cell ... to play an important role in the practice ... the old fashioned bone marrow transplants. Role of ...
(Date:5/28/2015)... SAN CARLOS, Calif. , May 28, 2015 ... genetic testing, today announced a study published in ... that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal ... in the first trimester. A ... indicates that complete molar pregnancies occur in about ...
(Date:5/28/2015)... May 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... and developing innovative therapeutics, primarily in the areas of ... public offering of 26 million units at a price ... proceeds of approximately $10.4 million. Each unit consists of ... overallotment purchase right to purchase 0.50 of a share ...
(Date:5/28/2015)... May 28, 2015 The Fertility Centers ... own Dr. Danielle Vitiello has taken on a new ... Dr. Vitiello will provide guidance, leadership, oversight and quality ... count Dr. Vitiello among our team of experienced reproductive ... CEO, Joseph A. Hill, M.D. “Her expertise and compassionate, ...
Breaking Biology Technology:Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 2First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ), ... and innovative anti-cancer pharmaceuticals in the rapidly,growing China ... its 2008,third quarter results on Thursday, November 6, ... Simcere,s chief executive officer, Jinsheng,Ren, and chief financial ...
... 2008 The most advanced and powerful electron microscope ... the new Canadian Centre for Electron Microscopy at McMaster ... world with a microscope of such a high calibre," ... Electron Microscopy, professor of Materials Science and Engineering, ...
... ANGELES, Oct. 20 Humanitarian, Dr. Gary Michelson,is ... animals,",says Aimee Gilbreath, Executive Director of Found Animals ... 501(c)3., Found Animals and its strategic partner ... announced the launch of The Michelson Prize in,Reproductive ...
Cached Biology Technology:Simcere Pharmaceutical Group to Announce Third Quarter 2008 Earnings on Thursday, November 6, 2008 2McMaster University unveils world's most advanced microscope 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 2Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 3Humanitarian Offers $75 Million for Single Dose Sterilization of Cats and Dogs 4
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
(Date:5/5/2015)... May 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, reminds investors and media ... Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held ... The three-day conference is organized into a ... in is themed Global Fraud: Where is the Trust ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... D.C.Recent climate modeling has shown that reducing the ... give the Earth a wetter climate in the ... scientists Long Cao and Ken Caldeira offers a ... atmospheric carbon dioxide (CO2) concentrations are decreasing. Their ...
... Scientists at the European Molecular Biology Laboratory (EMBL) in ... researchers to label any protein of their choice with ... in living cells, by introducing a single reactive artificial ... technique enables researchers to label even rare proteins very ...
... Biomechanics researchers Timothy Higham of Clemson University and Andrew ... in a forward, firm-footed stance across a slippery surface is ... move slowly. Approaching a slippery surface slowly hinders the necessary ... contact is made. The researchers studied helmeted guinea fowl ...
Cached Biology News:Cutting carbon dioxide helps prevent drying 2Don't shuffle on slippery surfaces, Clemson University, Charleston researchers say 2